News

Treatment with the drug Soliris (eculizumab) for atypical hemolytic uremic syndrome (aHUS) initially failed to ease the symptoms of a middle-age woman with AHUS and multiorgan involvement, a case study reported. Higher Soliris doses eventually eased disease symptoms in all organs except the kidneys, which had to be replaced…

A synthetic psychoactive drug was identified as the trigger that led to the onset of atypical hemolytic uremic syndrome (aHUS) in a 37-year-old man who was genetically prone to develop the condition, a case study in Croatia reported. “Our case is the first report of aHUS with proven ……

Pregnancy was identified as the trigger event for atypical hemolytic uremic syndrome (aHUS) that resulted in kidney damage for a genetically predisposed woman in her mid-20s, a U.S. case study reported. The patient had a clinical history of poorly managed high blood pressure and often failed to comply with…

A 38-year-old man developed atypical hemolytic uremic syndrome (aHUS) and end-stage kidney disease (ESKD) after receiving his first dose of AstraZeneca’s COVID-19 vaccine, according to a case report. The patient was admitted to a hospital in Saudi Arabia one week after being vaccinated. Tests revealed changes in blood parameters…

For the first time in South Korea, a patient who developed atypical hemolytic uremic syndrome (aHUS) after undergoing a kidney transplant was successfully treated with Soliris (eculizumab). “We report the first successful case of aHUS treatment in a kidney transplant recipient with early use of [Soliris] in South…

Preventive treatment with Soliris (eculizumab) before surgery dramatically improved kidney transplant outcomes in people with atypical hemolytic uremic syndrome (aHUS), according to a recent study. One year after the surgeries, 97% of transplanted kidneys still functioned in Soliris-treated patients. In those who did not receive preventive treatment, that…

A woman in her mid-30s with a twin pregnancy was diagnosed with atypical hemolytic uremic syndrome (aHUS) after she experienced complications following delivery by cesarean section. Two healthy girls were born, and the mother’s condition improved following treatment. But researchers noted that “this report underlines how crucial it is…

About half of the atypical hemolytic uremic syndrome (aHUS) patients had clinically relevant anxiety and more than a quarter met the criteria for post-traumatic stress disorder (PTSD), according to a recent study. “Our cross-sectional survey done a median of [six] years after acute … aHUS demonstrated a substantial burden…

COVID-19 may have triggered a relapse of atypical hemolytic uremic syndrome (aHUS) in a 31-year-old Japanese woman who was previously undiagnosed, according to a recent case study. The relapse occurred while the woman was positive for SARS-CoV-2, the virus that causes COVID-19, and was accompanied by disseminated, or diffuse,…

Soliris (eculizumab) was effective in managing atypical hemolytic uremic syndrome (aHUS), which arose in a man as a side effect of chemotherapy treatment with gemcitabine. “The mainstay management decision [for gemcitabine-related aHUS] is the prompt discontinuation of gemcitabine therapy, and while this is effective in some patients, complement…